Alyson Smith
Executive Director, Biology Callio Therapeutics
Seminars
Friday 6th November 2026
Panel Discussion: How Does Biology and Resistance Shape The Future Payload Landscape
9:30 am
- Will the future of ADC therapy be driven by a standardized sequence of dominant payload classes, or will tumor-specific biology determine payload choice from the outset?
- To what extent is resistance increasingly driven by payload mechanism rather than target biology, and does this undermine traditional linear sequencing models?
- How does tumor heterogeneity challenge the feasibility of a single, universal payload roadmap across indications?
- What does long-term success look like for next-generation payload strategies in terms of portfolio design, partnering models, and defining clinical value beyond potency?
- What are the implications for pipeline strategy, portfolio design, and payload partnering models?
